These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 5830808)

  • 1. Circulatory effects of d-lysergic acid diethylamide (LSD-25).
    Hassler O
    Psychopharmacologia; 1964 Oct; 6(4):311-8. PubMed ID: 5830808
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperthermic effects of D-lysergic acid diethylamide (LSD) and its derivatives in rabbits and rats.
    Hashimoto H; Hayashi M; Nakahara Y; Niwaguchi T; Ishii H
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):314-21. PubMed ID: 303504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and endocrine effects of lysergic acid diethylamide (LSD-25) on male rats.
    Weltman AS; Sackler AM
    J Endocrinol; 1966 Jan; 34(1):81-90. PubMed ID: 5948025
    [No Abstract]   [Full Text] [Related]  

  • 4. [[ffects of high doses of d-lysergic acid diethylamide on the respiration, blood circulation and central sympathicus tone of cats].
    Tauberger G; Klimmer OR
    Arzneimittelforschung; 1968 Dec; 18(12):1489-91. PubMed ID: 5756241
    [No Abstract]   [Full Text] [Related]  

  • 5. Cross tolerance between D-2-brom-lysergic acid diethylamide (BOL-148) and the D-diethylamide of lysergic acid (LSD-25).
    ISBELL H; MINER EJ; LOGAN CR
    Psychopharmacologia; 1959 Nov; 1():109-16. PubMed ID: 14405871
    [No Abstract]   [Full Text] [Related]  

  • 6. The effects of D-lysergic acid diethylamide on cerebral circulation and overall metabolism.
    SOKOLOFF L; PERLIN S; KORNETSKY C; KETY SS
    Ann N Y Acad Sci; 1957 Mar; 66(3):468-77. PubMed ID: 13425236
    [No Abstract]   [Full Text] [Related]  

  • 7. [The extrarenal circulatory effects of some diuretics and saluretics].
    Dragomir N; Deutsch G; Leuca V; Dreichlinger O; Rocsin M; Georgescu V; Hoffmann G
    Fiziol Norm Patol; 1965; 11(1):71-6. PubMed ID: 5843025
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of LSD-25 upon the cerebral blood flow and EEG in cats.
    INGVAR DH; SODERBERG U
    Experientia; 1956 Nov; 12(11):427-9. PubMed ID: 13384405
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of D-lysergic acid diethylamide (LSD-25) and 2-bromo-D-lysergic acid diethylamide (BOL-148) on sleeping behavior in rats].
    Loew DM; Depoortere H; Vigouret JM
    Naunyn Schmiedebergs Arch Pharmakol; 1970; 266(4):394-5. PubMed ID: 4326420
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of LSD on some immune processes and organ changes in mice infected with an influenza virus].
    Kocur J; Denys A; Szram S
    Med Dosw Mikrobiol; 1975; 27(1):85-8. PubMed ID: 1167925
    [No Abstract]   [Full Text] [Related]  

  • 11. Suppressive effects of pyrilamine maleate and d-lysergic acid diethylamide (LSD-25) on early corneal lesions produced in vitro by Newcastle disease virus (NDV) and compound 48/80.
    OH JO; EVANS CA
    Virology; 1960 Jan; 10():127-43. PubMed ID: 14428440
    [No Abstract]   [Full Text] [Related]  

  • 12. Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain.
    Hungen KV; Roberts S; Hill DF
    Brain Res; 1975 Aug; 94(1):57-66. PubMed ID: 238721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual actions of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL) and methysergide on dorsal root potentials evoked by stimulation of raphe nuclei.
    Larson AA; Chinn C; Proudfit HK; Anderson EG
    J Pharmacol Exp Ther; 1981 Apr; 217(1):99-104. PubMed ID: 6110778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inhibition of post-ganglionic motor transmission in the mammalian vas deferens by D-lysergic acid diethylamide.
    Ambache N; Dunk LP; Verney J; Zar MA
    J Physiol; 1973 Jun; 231(2):251-70. PubMed ID: 4352765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [D-Lysergic acid diethylamide (LSD). 2. Clinical aspects].
    GROF S; VOJTECHOVSKY M; VOTAVA Z
    Lek Veda Zahr; 1960; 11():245-51 contd. PubMed ID: 13858660
    [No Abstract]   [Full Text] [Related]  

  • 16. Enzymic formation of dehydrogenated and hydroxylated metabolites from lysergic acid diethylamide by rat liver microsomes.
    Inoue T; Niwaguchi T; Murata T
    Xenobiotica; 1980 May; 10(5):343-8. PubMed ID: 7415216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
    Burris KD; Sanders-Bush E
    Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of noradrenaline release by lysergic acid diethylamide.
    Hughes J
    Br J Pharmacol; 1973 Dec; 49(4):706-8. PubMed ID: 4788042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the liver protein pattern due to lysergic acid diethylamide (LSD).
    MISSERE G; TONINI G; BABBINI M
    Experientia; 1961 Jan; 17():33-4. PubMed ID: 13771306
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of lysergic acid diethylamide (LSD-25) on morphine induced bradycardia.
    Jaju BP; Srimal RC; Dhawan KN; Gupta GP
    Jpn J Pharmacol; 1967 Dec; 17(4):678-9. PubMed ID: 5301357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.